MYC/BCL2 expression induces CCL2 secretion in human DLBCL cells. (A-B) CCL2 expression in MYC^high/BCL2^high OCI-LY8 and DOHH2 cells and in MYC^low/BCL2^low HT and SUDHL-10 in basal and activated status (20 ng/mL IL-4 + 5 μg/mL IgM) was measured using qRT-PCR, enzyme-linked immunosorbent assay (ELISA), and western blotting. (C-E) MYC^low/BCL2^low cells were transfected with MYC- and/or BCL2-expression vectors and then subjected to qRT-PCR, western blotting, and immunofluorescence (IF) staining to assess CCL2 expression (scale bar, 10 μm). (F-G) MYC^low/BCL2^low cells were transfected with MYC- and/or BCL2-expression vectors in the presence or absence of the NF-kB activation inhibitor JSH-23 (20 μM, 24 hours). (H-K) MYC^high/BCL2^high cells were treated with bioavailable inhibitors for MYC and BCL2 (10 nM venetoclax, 100 nM JQ-1, and 25 nM fimpinostat for 48 hours) and then subjected to qRT-PCR, ELISA, western blotting, and IF staining to assess the CCL2 expression (scale bar, 10 μm). The data are presented as mean ± standard error of the mean (SEM) of 3 independent experiments. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. DAPI, 4′,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide.